Among these developments is trastuzumab deruxtecan (brand name: Enhertu), which offers new hope specifically for patients who harbor HER2 mutations in their lung cancer, a type once challenging to ...

Enhertu, an engineered HER2-directed antibody-drug conjugate, is approved for several advanced or metastatic cancers, including HER2-positive breast cancer. Safety concerns for Enhertu include ...

The company is betting that the alternative cytotoxic payload in its ADC can overcome resistance in patients who relapse on Enhertu.

Companies like AstraZeneca, Daiichi Sankyo, Pfizer and Merck are learning from previous setbacks in the ADC space to improve ...

References: Enhertu® (fam-trastuzumab deruxtecan-nxki) approved in the US as first HER2-directed therapy for patients with HER2-low or HER2-ultralow metastatic breast cancer following disease ...

The data – presented in a keynote at the ESMO cancer congress – also showed a three-fold improvement in progression-free survival – 25.1 months for Enhertu versus 7.2 months for Roche's drug ...

Interstitial lung disease (ILD) and pneumonitis, ... HER2-low, or HER2-ultralow breast cancer treated with ENHERTU 5.4 mg/kg, 24% were ≥65 years and 4.9% were ≥75 years.

ENHERTU (5.4mg/kg) is approved in more than 50 countries worldwide for the treatment of adult patients with unresectable or metastatic non-small cell lung cancer (NSCLC) whose tumors have ...

Interstitial lung disease (ILD) and pneumonitis, ... HER2-low, or HER2-ultralow breast cancer treated with ENHERTU 5.4 mg/kg, 24% were ≥65 years and 4.9% were ≥75 years.